Loading Events

« All Events



In response to growing pressure to manage healthcare budgets, especially in the post COVID environment, many countries are implementing or reforming pricing and reimbursement policies as part of efforts to contain healthcare costs. National healthcare expenditure in Singapore has almost doubled from $10 billion in 2010 to $21 billion in 2018 and will almost triple to $59 billion in 2030.  

At the MOH annual work plan seminar on May 25, Health Minister Ong Ye Kung emphasised “Beyond quality to value” as a key part of the strategy to help control healthcare expenditure. He highlighted the importance of using drugs and treatments that are the most cost-effective and ensuring that prices charged to match the outcomes they deliver.  HTA plays a critical role in this process. HTA is an established scientific research methodology to inform policy and clinical decision-making on the relative value of new health technologies, such as drugs, devices and medical services, compared to existing standards of care. 

Sound evidence for informed investment decision-making in healthcare is critical. When designed well and used appropriately, HTA provides policymakers with evidence to inform decision-making and guidance on reimbursement of new medicines and technologies.  However, with the rapid pace and scale of technological development, traditional approaches to evidence production, review and synthesis can quickly become outdated by innovative technologies and advances in clinical management. All participants in the healthcare ecosystem are committed to the objective of keeping the Singapore healthcare system sustainable long term.  When traditional methods of HTA assessment are no longer relevant, a ‘one-size-fits-all approach’ risks patients not receiving the very best therapies and health outcomes possible and the healthcare system not gaining full benefits in return. 

This educational discussion focuses on how the evidence ecosystem (globally and in Singapore) is adapting to meet healthcare systems’ challenges of today, and tomorrow. 

The objective of this webinar is to discuss how Singapore can power its ambition toward innovation while maintaining healthcare ecosystem sustainability. This session will review global HTA developments across various therapy areas and discuss how Singapore can continue adapting to meet the healthcare system challenges of today and tomorrow. This theme reflects the changing times we live in, the rapid pace of technology advances and of course the increase in healthcare spending which has been forced by COVID-19. 


4.15 pm Waiting room opens
4.30 pm Welcome Remark – EuroCham
4:35 pm Opening Remark

  • Mr Anbu Srinivasan (Chair of EuroCham Healthcare Committee)

4.40 pm Presentations 

  • Ms Tania Krivasi (AstraZeneca)

Evolution of HTA: Capturing Value in Value-Based Assessments

  • Mr Jek Fong (Roche Singapore) 

Targeted population pathways such as cancer and rare disease

  • Dr Susanne Miller (GSK) and Mr Yu-Fan Ho (GSK)

Prevention pathways in the post COVID era – novel antibiotics and vaccines

5.20 pm Moderated Panel Discussion and Q&A 

  • Ms Sol Magaz (EY-Parthenon)

5:55 pm Closing Remarks


Ms Tania Krivasi
Market Access Lead, Asia Area & Singapore
Tania Krivasi is a health economist and market access specialist with 10 years of work experience within both the pharmaceutical industry and healthcare consulting. She is currently the market access lead for Singapore and Asia Area at AstraZeneca. Prior to joining AZ in 2020, she spent 5 years with Roche at different global, regional and country roles in HTA, health economics and access functions. Tania also worked in healthcare consulting in London, where she led multiple HEOR HEOR projects. Tania holds a masters in health economics from the University of York and a Bachelors in Economics from the University of Macedonia in Greece.


Mr Jek Fong
Director – Patient Access and Personalized Healthcare

Jek started his career in leukaemia research with NUS and has more than a decade of experience in various roles within the pharmaceutical and medical device industries. Jek spent the last 4 years as Director of Market Access and Personalized Healthcare in Roche and is a passionate servant leader building highly engaged teams driven by a singular purpose to enable access to precision medicine in Singapore. Jek graduated with a BSc in Biomedical Science, and holds an executive MBA and graduate diploma in Strategic Marketing. 



Dr Susanne Miller
Director of Government Affairs and Communications
GlaxoSmithKline (GSK)

Susanne Miller (PhD MBA) is Director of Government Affairs and Communications for GSK, Global Pharma. Her 15 year career has spanned the innovation lifecycle from R&D to product development, sales & marketing, market access, government affairs and strategic communications. She has worked across multiple geographies including the Asia Pacific, Emerging Markets and Europe and has lived in Singapore since 2013. Susanne enjoys leading teams through complexity in rapidly changing environments.



Mr Yu-Fan Ho
Regional Health Outcomes Manager
GlaxoSmithKline (GSK)
Yu-Fan Ho is currently the Regional Health Outcomes Manager for Asia-Pacific at GlaxoSmithKline. He performs a cross-therapeutic role focused on the delivery of economic evaluation frameworks, outcome measures, and population-based disease epidemiology and burden evidence to support medicines and vaccines approaching registration, launch, reimbursement and lifecycle management. He has also held previous roles in policy research in the Ministry of Health and Welfare, Taiwan as well as in medical affairs at Roche Diagnostics, UK supporting the development of global value dossiers for Oncology companion diagnostic portfolios. Yu-Fan obtained his MPH specializing in Health Economics and Health Service Management at the London School of Hygiene and Tropical Medicine, UK.



Ms Sol Magaz

Sol is a partner co-leading the Healthcare and Life Sciences sector within EY-Parthenon in Singapore. Sol has over 20 years of consulting experience serving a broad range of clients in the pharmaceutical, biotechnology, med-tech and provider subsectors, on a variety of issues, from strategy to operations across Asia and Emerging Markets.
Sol started her career as a health economist and prior to joining EY-Parthenon 18 months ago, Sol spent most of her career in the life sciences and healthcare practise of A.T. Kearney in London and then in IQVIA in Singapore where she was leading the Consulting team. 
Sol has worked extensively in funding and affordability strategy, Value-Based Pricing and innovative contracting and access solutions as well as supported industry-government negotiations with corporates and trade associations across the world.


Student tickets are available for this event.

Students from partnering universities are invited to join with a discount rate. Partnering universities; NUS, NTU, SMU, EDHEC, ESSEC, IMD & INSEAD.

  • Please sign up with your university-issued email address
  • Enter your institution under “company”
  • Enter your major/ programme under “designation” 
  • Select “Student Ticket”


Registration Guidelines –

Please follow these simple steps for easy registration to the on-demand webinar.

Step 1: Register below. You will receive an automated registration confirmation email from EuroCham.

Step 2: A Zoom link will be sent if payment has been received. (Payment by PayPal, PayNow/ PayLah/ QR Code preferred). Please watch out for this second email.

Step 3: Using the link provided in the second email, click on the link before 29 October 2021. 

Registration is binding and payment is non-refundable.